This section is intended for media and financial analysts
Search Press releases
25 Sep 2023
UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan
UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio
